Jerusalem, Israel.

NovellusDx announced that the Examining Division of the European Patent Office intends to grant it a European Patent For: “Methods and systems for identifying patient-specific driver mutations” (patent number 2946207). This approval comes after receiving a similar approval from the Israeli Patent Office earlier this year and protects the innovative advantage of the technology developed by NovellusDx. The patent, the first of a large patent family, is fully owned by the company and protects its core technology.

The methods disclosed in the patent relate to the identification of functionally important mutations of the patient using the FACT test.
“This patent is part of our main patent family”, says Dr. Tarcic, “and protects the main kernel of our system to identify driver mutations by examining their effect in live cells”.